IXICO has developed, in collaboration with Imperial College London, technology to provide a subject-specific model* for estimated disease progression of an individual subject. This approach brings to life the hypothetical models proposed at the population level for the trajectories observed for different biomarkers in a given CNS disease. The method estimates a trajectory model based on a large reference database of relevant subjects and novel machine learning technology. This approach allows the following applications:
*This technology is exclusively licensed to IXICO from Imperial College London.